Loading...
Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy.
Herrmann, Jennifer Elnakady, Yasser A Wiedmann, Romina M Ullrich, Angelika Rohde, Manfred Kazmaier, Uli Vollmar, Angelika M Müller, Rolf
Herrmann, Jennifer
Elnakady, Yasser A
Wiedmann, Romina M
Ullrich, Angelika
Rohde, Manfred
Kazmaier, Uli
Vollmar, Angelika M
Müller, Rolf
Files
Loading...
Open Access publication
Adobe PDF, 1.91 MB
Other Titles
Abstract
Pretubulysin is a natural product that is found in strains of myxobacteria in only minute amounts. It represents the first enzyme-free intermediate in the biosynthesis of tubulysins and undergoes post-assembly acylation and oxidation reactions. Pretubulysin inhibits the growth of cultured mammalian cells, as do tubulysins, which are already in advanced preclinical development as anticancer and antiangiogenic agents. The mechanism of action of this highly potent compound class involves the depolymerization of microtubules, thereby inducing mitotic arrest. Supply issues with naturally occurring derivatives can now be circumvented by the total synthesis of pretubulysin, which, in contrast to tubulysin, is synthetically accessible in gram-scale quantities. We show that the simplified precursor is nearly equally potent to the parent compound. Pretubulysin induces apoptosis and inhibits cancer cell migration and tubulin assembly in vitro. Consequently, pretubulysin appears to be an ideal candidate for future development in preclinical trials and is a very promising early lead structure in cancer therapy.
Citation
Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy. 2012, 7 (5):e37416 PLoS ONE
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1932-6203
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Archived with thanks to PloS one